ERLOTINIB (TARCEVA)

Course overview

Erlotinib is U.S. FDA-approved to treat locally advanced/metastatic non-small cell lung cancer (NSCLC) as second-line monotherapy; and in combination with gemcitabine as first-line therapy for locally advanced, unresectable, or metastatic pancreatic cancer. This continuing education module is designed to give the reader/learner an increased understanding of erlotinib. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.